Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer

Abstract Introduction Liposomal irinotecan promotes controlled sustained release of irinotecan (CPT-11), therefore, we hypothesize that the therapeutic index (quantitative measurement of the relative efficacy/safety ratio of a drug) will be higher for liposomal than non-liposomal irinotecan. Methods...

Full description

Bibliographic Details
Main Authors: Sandrine Barbier, Benjamin Beaufils, Ricardo de Miguel, Melissa Reyre, Yannick Le Meitour, Andreanne Lortie, Marc Hillairet de Boisferon, Sophie Chaumeron, Anne Espirito, Lina Fossati, Pauline Lagarde, Stephan Klinz, Arunthathi Thiagalingam, Stéphane Lezmi, Florence Meyer-Losic
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-01-01
Series:Oncology and Therapy
Subjects:
Liposomal irinotecan
Pancreatic cancer
Patient-derived xenograft
Therapeutic index
Tumor model
Online Access:https://doi.org/10.1007/s40487-022-00215-2

Internet

https://doi.org/10.1007/s40487-022-00215-2

Similar Items